ArticleInfection and immunity2013
Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.
Article in Infection and immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 99 citations in OpenAlex.
- Hydroxypropyl starch enhances gut health in geese.Poultry science · 2026Article
- The roles of gut microbiota and their metabolites in uric acid-related metabolic diseases: mechanisms and therapeutic targets.Frontiers in microbiology · 2026Review
- The microbiota-gut-brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets.The FEBS journal · 2025Review
- Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys.Frontiers in pharmacology · 2025Review
- Comparative study of milk microbiota and metabolome in long-lived dairy cows with different persistent production capacities.Frontiers in microbiology · 2025Article
- Microbiota and metabolome dynamics induced by Shiga toxin-producingMicrobial cell (Graz, Austria) · 2025Article
- Mechanism of intestinal flora affecting SLC2A9 transport function to promote the formation of hyperuricemia.Heliyon · 2024Article
- Analysis of bb0556 Expression and Its Role During Borrelia burgdorferi Mammalian Infection.Molecular microbiology · 2024Article
- Structural basis of transcriptional regulation by UrtR in response to uric acid.Nucleic acids research · 2024Article
- Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: Insights and therapeutic strategies.World journal of gastroenterology · 2024Review
- Emerging Roles of Xanthine Oxidoreductase in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- Nutrition, gastrointestinal microorganisms and metabolites in mastitis occurrence and control.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Review
- Effect of konjac glucomannan on gut microbiota from hyperuricemia subjectsFrontiers in nutrition · 2024Article
- Article
- Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies.Scientifica · 2024Review
- Role of Extracellular DNA in Bacterial Response to SOS-Inducing Drugs.Antibiotics (Basel, Switzerland) · 2023Article
- Article
- 16S rRNA and Metagenomics Combined with UPLC-Q/TOF-MS Metabolomics Analysis Reveals the Potential Mechanism of Radix Astragali Against Hyperuricemia in Mice.Drug design, development and therapy · 2023Article
- Effect of Bining decoction on gouty nephropathy: a network pharmacology analysis and preliminary validation of gut microbiota in a mouse model.Annals of translational medicine · 2022Article
- The Global Regulator MftR Controls Virulence and Siderophore Production in Burkholderia thailandensis.Journal of bacteriology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Xanthine oxidase (XO), also known as xanthine oxidoreductase, has long been considered an important host defense molecule in the intestine and in breastfed infants. Here, we present evidence that XO is released from and active in intestinal tissues and fluids in response to infection with enteropathogenic Escherichia coli (EPEC) and Shiga-toxigenic E. coli (STEC), also known as enterohemorrhagic E. coli (EHEC). XO is released into intestinal fluids in EPEC and STEC infection in a rabbit animal model. XO activity results in the generation of surprisingly high concentrations of uric acid in both cultured cell and animal models of infection. Hydrogen peroxide (H(2)O(2)) generated by XO activity triggered a chloride secretory response in intestinal cell monolayers within minutes but decreased transepithelial electrical resistance at 6 to 22 h. H(2)O(2) generated by XO activity was effective at killing laboratory strains of E. coli, commensal microbiotas, and anaerobes, but wild-type EPEC and STEC strains were 100 to 1,000 times more resistant to killing or growth inhibition by this pathway. Instead of killing pathogenic bacteria, physiologic concentrations of XO increased virulence by inducing the production of Shiga toxins from STEC strains. In vivo, exogenous XO plus the substrate hypoxanthine did not protect and instead worsened the outcome of STEC infection in the rabbit ligated intestinal loop model of infection. XO released during EPEC and STEC infection may serve as a virulence-inducing signal to the pathogen and not solely as a protective host defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.